Search Results for: xarelto
Relugolix with estradiol and norethisterone acetate (Ryeqo®). HTA ID: 24018
Trastuzumab Deruxtecan (Enhertu®). HTA ID: 25039
Tremelimumab (Imjudo®) in combination with durvalumab (Imfinzi®). HTA ID: 23073
Pembrolizumab (Keytruda®). HTA ID: 23070
Zanubrutinib (Brukinsa®) for marginal zone lymphoma. HTA ID: 23072
Cabozantinib (Cabometyx®) in combination with nivolumab (Opdivo®). HTA ID: 22018
NCPE Annual Symposium 2025
The Annual NCPE Symposium will take place this year on Thursday 16th October 2025 at the Cusack Suite in Croke Park: Please complete the Registration form Symposium 2025 and return to [email protected]
Omaveloxolone (Skyclarys®). HTA ID: 24033
Lecanemab (Leqembi®). HTA ID: 24052
Glofitamab (Columvi®) in combination with gemcitabine and oxaliplatin. HTA ID: 25037
Selpercatinib (Retsevmo®) for advanced RET-mutant medullary thyroid cancer. HTA ID: 25034a
Selpercatinib (Retsevmo®) for advanced RET fusion-positive thyroid cancer. HTA ID: 25034b
Tezepelumab (Tezspire®). HTA ID: 23025
Elranatamab (Elrexfio®). HTA ID: 23066
Faricimab (Vabysmo ®) for visual impairment due to diabetic macular oedema. HTA ID: 22061
Faricimab (Vabysmo ®) for neovascular (wet) age-related macular degeneration. HTA ID: 22060
Omeprazole (Appizped®). HTA ID: 25038
Dostarlimab (Jemperli®) in combination with carboplatin and paclitaxel. HTA ID: 24004
Capivasertib (Truqap®). HTA ID: 24015
Tirzepatide (Mounjaro®). HTA ID: 24024
Nivolumab (Opdivo®) subcutaneous. HTA ID: 25036
Sodium thiosulfate (Pedmarqsi®). HTA ID: 25002
Anifrolumab (Saphnelo®). HTA ID: 23027
Tislelizumab (Tevimbra®). HTA ID 25033
Semaglutide (Wegovy®). HTA ID: 25024
Sulthiame (Ospolot®) oral suspension. HTA ID: 25030
Talquetamab (Talvey®). HTA ID: 23057
Tucatinib (Tukysa®). HTA ID: 22058
Assessment Status NCPE assessment ongoing HTA ID 22058 Drug Tucatinib Brand Tukysa® Indication In combination with trastuzumab and capecitabine for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer wo have received at least two prior anti-HER2 treatment regimens. Rapid review commissioned 23/08/2022 Rapid review completed […]
Pembrolizumab (Keytruda®). HTA ID: 24013
Pembrolizumab (Keytruda®). HTA ID: 25032
Avapritinib (Ayvakyt®). HTA ID: 25031
Sotatercept (Winrevair ®). HTA ID: 24041
Pembrolizumab (Keytruda®). HTA ID: 23056
Melphalan flufenamide (Pepaxti®). HTA ID: 25028
Rimegepant (Vydura®). HTA ID: 22051
Olaparib (Lynparza®) in combination with abiraterone and prednisone. HTA ID: 23029
Tirzepatide (Mounjaro®). HTA ID: 24003
Assessment Status Awaiting response from Applicant HTA ID 24003 Drug Tirzepatide Brand Mounjaro® Indication Tirzepatide (Mounjaro®) for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise • as monotherapy when metformin is considered inappropriate due to intolerance or contraindications • in […]
Cipaglucosidase alfa in combination with miglustat (Pombiliti® in combination with Opfolda®). HTA ID 25027
Update to the Budget Impact Model Template
Version 2.2 of the Budget Impact Model was published on 2nd May 2025 and replaces version 2.1. The new version is available here. The NCPE have published the NCPE-Budget-Impact-Guideline The aim of this guideline is to provide guidance on the conduct of a drug budget impact analysis (BIA). For those […]